Telix Pharmaceuticals (TLX) Competitors $9.38 -0.17 (-1.81%) As of 10:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock TLX vs. VTRS, ASND, RDY, QGEN, BBIO, MRNA, VRNA, ELAN, ROIV, and RVMDShould you be buying Telix Pharmaceuticals stock or one of its competitors? The main competitors of Telix Pharmaceuticals include Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Telix Pharmaceuticals vs. Its Competitors Viatris Ascendis Pharma A/S Dr. Reddy's Laboratories QIAGEN BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Telix Pharmaceuticals (NASDAQ:TLX) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends. Does the media favor TLX or VTRS? In the previous week, Telix Pharmaceuticals had 30 more articles in the media than Viatris. MarketBeat recorded 34 mentions for Telix Pharmaceuticals and 4 mentions for Viatris. Viatris' average media sentiment score of 0.12 beat Telix Pharmaceuticals' score of -0.22 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 2 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Viatris 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts prefer TLX or VTRS? Telix Pharmaceuticals currently has a consensus price target of $22.33, suggesting a potential upside of 138.17%. Viatris has a consensus price target of $10.40, suggesting a potential downside of 1.07%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Telix Pharmaceuticals is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telix Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Which has better earnings and valuation, TLX or VTRS? Telix Pharmaceuticals has higher earnings, but lower revenue than Viatris. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelix Pharmaceuticals$637.77M4.98$32.93MN/AN/AViatris$14.74B0.83-$634.20M-$2.90-3.63 Is TLX or VTRS more profitable? Telix Pharmaceuticals has a net margin of 0.00% compared to Viatris' net margin of -24.57%. Viatris' return on equity of 16.54% beat Telix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Telix PharmaceuticalsN/A N/A N/A Viatris -24.57%16.54%7.06% Do institutionals and insiders hold more shares of TLX or VTRS? 79.9% of Viatris shares are owned by institutional investors. 0.1% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryTelix Pharmaceuticals beats Viatris on 7 of the 13 factors compared between the two stocks. Get Telix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TLX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLX vs. The Competition Export to ExcelMetricTelix PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.18B$3.09B$5.69B$9.67BDividend YieldN/A2.28%6.66%4.48%P/E RatioN/A21.0782.8526.35Price / Sales4.98403.97551.97112.92Price / Cash83.6343.5325.6628.92Price / Book8.379.8711.596.08Net Income$32.93M-$54.01M$3.27B$265.75M7 Day Performance-25.22%0.15%0.48%-0.05%1 Month Performance-28.15%9.41%8.68%5.82%1 Year PerformanceN/A8.06%59.42%17.97% Telix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLXTelix PharmaceuticalsN/A$9.38-1.8%$22.33+138.2%N/A$3.18B$637.77M0.00N/AAnalyst RevisionHigh Trading VolumeVTRSViatris1.7884 of 5 stars$10.55+1.3%$10.40-1.4%-12.7%$12.30B$14.74B-3.6432,000ASNDAscendis Pharma A/S2.5464 of 5 stars$194.27+0.2%$243.36+25.3%+40.3%$11.89B$393.54M-37.651,017News CoveragePositive NewsRDYDr. Reddy's Laboratories2.8697 of 5 stars$14.20-0.1%$16.95+19.4%-15.0%$11.86B$3.81B21.5127,811News CoveragePositive NewsQGENQIAGEN3.8021 of 5 stars$46.53+0.9%$49.69+6.8%+4.7%$10.34B$1.98B27.495,765News CoveragePositive NewsBBIOBridgeBio Pharma4.1755 of 5 stars$51.76-1.5%$62.18+20.1%+85.9%$9.89B$221.90M-12.66400Positive NewsMRNAModerna4.5094 of 5 stars$24.09-1.6%$42.88+78.0%-68.9%$9.37B$3.24B-3.205,800VRNAVerona Pharma PLC American Depositary Share2.2361 of 5 stars$105.91+0.0%$109.00+2.9%+285.4%$9.16B$42.28M-106.9830News CoveragePositive NewsELANElanco Animal Health2.7654 of 5 stars$18.38-0.4%$17.33-5.7%+18.8%$9.12B$4.44B21.379,000Positive NewsHigh Trading VolumeROIVRoivant Sciences3.2877 of 5 stars$11.93-0.1%$16.50+38.3%-2.5%$8.15B$29.05M-17.04860News CoveragePositive NewsAnalyst ForecastRVMDRevolution Medicines4.4181 of 5 stars$37.97-0.9%$69.92+84.2%-10.9%$7.10B$11.58M-8.44250News CoveragePositive News Related Companies and Tools Related Companies VTRS Alternatives ASND Alternatives RDY Alternatives QGEN Alternatives BBIO Alternatives MRNA Alternatives VRNA Alternatives ELAN Alternatives ROIV Alternatives RVMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLX) was last updated on 9/2/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHave You Seen This? Trump Schedules 'Stock Market Reset' For Sept. 30Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Telix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TLX Stock Alerts